| Vaccine |
Immunization route |
No. of doses |
Developer |
Status |
References |
| Shigellosis |
|
|
|
|
|
| Attenuated S. sonnei strain WRSS1 |
Oral |
2 |
Walter Reed Army Institute of Research |
Phase II |
[70] |
| Attenuated S. flexneri2a strain CVD 1208S |
Oral |
2 |
Center for Vaccine Development, University of Maryland |
Phase I |
[74] |
| Attenuated S. flexneri2a strain SC602 |
Oral |
1-2 |
Pasteur Institute |
Phase II |
[71] |
| Attenuated S. dysenteriae 1 strain SC599 |
Oral |
2 |
Pasteur Institute |
Phase II |
[73] |
| Shigellaglycoconjugates (O polysaccharide covalently linked to carrier protein) |
Intra-muscular |
2 |
National Institute ofHealth and Human Development |
Phase III |
[65] |
| Shigella invasion complex (Invaplex) |
Nasal |
3 |
Walter Reed Army Institute of Research |
Phase I |
[68] |
| Proteosomes (OMP of Group B meningitides) to which S. sonnei or S. flexneri2a LPS is adsorbed |
Nasal |
2 |
ID Biomedical* |
Phase I |
[69] |
| ETEC diarrhea |
|
|
|
|
|
| B subunit-inactivated whole fimbriated ETEC combination |
Oral |
2 |
University of Goteborg and SBL |
Phase III |
[82] |
| Attenuated fimbriated non-toxigenic E. coli (derived from ETEC) |
Oral |
2 |
Cambridge Biostability Ltd. |
Phase I |
[88] |
| Attenuated Shigella strains expressing ETEC fimbrial colonization factors and B subunit of LTh** |
Oral |
2 |
Center for Vaccine Development, University of Maryland |
Phase I |
[86] |
